{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:13:10Z","timestamp":1761901990824,"version":"build-2065373602"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T00:00:00Z","timestamp":1664323200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["AA007471"],"award-info":[{"award-number":["AA007471"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.msard.2022.104195","type":"journal-article","created":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T13:47:20Z","timestamp":1664200040000},"page":"104195","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Longitudinal COVID-19 immune trajectories in patients with neurological autoimmunity on anti-CD20 therapy"],"prefix":"10.1016","volume":"68","author":[{"given":"Sam A.","family":"Bazzi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cole","family":"Maguire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nisha","family":"Holay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janelle","family":"Geltman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerin","family":"Hurley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"DiPasquale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Abigania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Olson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren I.R.","family":"Ehrlich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd A.","family":"Triplett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"Melamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.msard.2022.104195_bib0001","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1038\/s41591-021-01507-2","article-title":"Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy","volume":"27","author":"Apostolidis","year":"2021","journal-title":"Nat. Med."},{"issue":"11","key":"10.1016\/j.msard.2022.104195_bib0002","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1038\/s41591-021-01507-2","article-title":"Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy","volume":"27","author":"Apostolidis","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.msard.2022.104195_bib0003","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00736","article-title":"Differential expression of IgM and IgD discriminates two subpopulations of human circulating IgM+IgD+CD27+ B cells that differ phenotypically, functionally, and genetically","volume":"11","author":"Bautista","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2022.104195_bib0004","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.imlet.2021.05.006","article-title":"B cells as target for immunotherapy in rheumatic diseases\u2013current status","volume":"236","author":"Bryl","year":"2021","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.msard.2022.104195_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103413","article-title":"B cell depleters attenuate the humoral response to SARS-CoV-2 vaccines in multiple sclerosis patients: a case-control study","volume":"57","author":"Conte","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"6529","key":"10.1016\/j.msard.2022.104195_bib0006","doi-asserted-by":"crossref","first-page":"eabf4063","DOI":"10.1126\/science.abf4063","article-title":"Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection","volume":"371","author":"Dan","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.msard.2022.104195_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103636","article-title":"Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy","volume":"73","author":"Gadani","year":"2021","journal-title":"EBioMedicine"},{"issue":"7","key":"10.1016\/j.msard.2022.104195_bib0008","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000603","article-title":"COVID-19 in patients receiving CD20-depleting immunochemotherapy for B cell lymphoma","volume":"5","author":"Gaitzsch","year":"2021","journal-title":"Hemasphere"},{"issue":"7","key":"10.1016\/j.msard.2022.104195_bib0009","doi-asserted-by":"crossref","first-page":"e603","DOI":"10.1097\/HS9.0000000000000603","article-title":"COVID-19 in patients receiving CD20-depleting Immunochemotherapy for B cell Lymphoma","volume":"5","author":"Gaitzsch","year":"2021","journal-title":"Hemasphere"},{"issue":"7","key":"10.1016\/j.msard.2022.104195_bib0010","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","article-title":"Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals","volume":"181","author":"Grifoni","year":"2020","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.msard.2022.104195_bib0011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v040.i03","article-title":"Dates and times made easy with lubridate","volume":"40","author":"Grolemund","year":"2011","journal-title":"J Stat Softw"},{"key":"10.1016\/j.msard.2022.104195_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103682","article-title":"Humoral and cellular immunity in convalescent and vaccinated COVID-19 people with multiple sclerosis: effects of disease modifying therapies","volume":"59","author":"Habek","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2022.104195_bib0013","unstructured":"Hadley Wickham, D.S., Scales: scale functions for visualization. (Version 1.1.1) (2022)."},{"key":"10.1016\/j.msard.2022.104195_bib0014","unstructured":"Healthineers, S., SARS-CoV-2 IgG (sCOVG): assay for the detection of IgG antibodies to SARS-CoV-2 (2022)."},{"key":"10.1016\/j.msard.2022.104195_bib0015","article-title":"Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations","author":"K\u00f6nig","year":"2021","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2022.104195_bib0016","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.01578","article-title":"Prolonged course of COVID-19-associated pneumonia in a B cell depleted patient after rituximab","volume":"10","author":"Kos","year":"2020","journal-title":"Front. Oncol."},{"issue":"5","key":"10.1016\/j.msard.2022.104195_bib0017","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2008-02-078071","article-title":"B lymphocytes: how they develop and function","volume":"112","author":"LeBien","year":"2008","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.msard.2022.104195_bib0018","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41573-020-00092-2","article-title":"B cell depletion therapies in autoimmune disease: advances and mechanistic insights","volume":"20","author":"Lee","year":"2021","journal-title":"Nat. Rev. Drug Discovery"},{"key":"10.1016\/j.msard.2022.104195_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102323","article-title":"Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report","volume":"44","author":"Lucchini","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2022.104195_bib0020","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.834981","article-title":"Antigen specific humoral and cellular immunity following SARS-CoV-2 vaccination in ANCA-associated vasculitis patients receiving B cell depleting therapy","volume":"13","author":"Marty","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2022.104195_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103560","article-title":"Recall response to COVID-19 antigen is preserved in people with multiple sclerosis on anti-CD20 medications - a pilot study","volume":"59","author":"Moser","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2022.104195_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103560","article-title":"Recall response to COVID-19 antigen is preserved in people with multiple sclerosis on anti-CD20 medications \u2013 a pilot study","volume":"59","author":"Moser","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"10","key":"10.1016\/j.msard.2022.104195_bib0023","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1136\/annrheumdis-2021-220781","article-title":"SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T cell-mediated immunity","volume":"80","author":"Mrak","year":"2021","journal-title":"Ann. Rheum. Dis."},{"issue":"10","key":"10.1016\/j.msard.2022.104195_bib0024","doi-asserted-by":"crossref","first-page":"5982","DOI":"10.4049\/jimmunol.0801859","article-title":"Novel human transitional B cell populations revealed by B cell depletion therapy","volume":"182","author":"Palanichamy","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.msard.2022.104195_bib0025","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.01941","article-title":"T Cell\/B Cell collaboration and autoimmunity: an intimate relationship","volume":"9","author":"Petersone","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2022.104195_bib0026","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3389\/fonc.2018.00163","article-title":"Past, present, and future of rituximab\u2014the world's first oncology monoclonal antibody therapy","volume":"8","author":"Pierpont","year":"2018","journal-title":"Front. Oncol."},{"issue":"10","key":"10.1016\/j.msard.2022.104195_bib0027","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1136\/annrheumdis-2021-220677","article-title":"SARS-COV-2 vaccination after stem cell transplantation for scleroderma","volume":"80","author":"Rimar","year":"2021","journal-title":"Ann. Rheum. Dis."},{"issue":"4","key":"10.1016\/j.msard.2022.104195_bib0028","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.156978","article-title":"Multiple sclerosis therapies differentially affect SARS-CoV-2 vaccine\u2013induced antibody and T cell immunity and function","volume":"7","author":"Sabatino Jr","year":"2022","journal-title":"JCI Insight"},{"issue":"8","key":"10.1016\/j.msard.2022.104195_bib0029","doi-asserted-by":"crossref","first-page":"713","DOI":"10.2217\/imt-2017-0178","article-title":"Consequences of B cell-depleting therapy: hypogammaglobulinemia and impaired B cell reconstitution","volume":"10","author":"Sacco","year":"2018","journal-title":"Immunotherapy"},{"key":"10.1016\/j.msard.2022.104195_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102195","article-title":"B cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran","volume":"43","author":"Safavi","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2022.104195_bib0031","doi-asserted-by":"crossref","DOI":"10.1177\/13524585221102918","article-title":"Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies","author":"Schiavetti","year":"2022","journal-title":"Mult. Scler."},{"issue":"4","key":"10.1016\/j.msard.2022.104195_bib0032","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.cell.2021.01.007","article-title":"Adaptive immunity to SARS-CoV-2 and COVID-19","volume":"184","author":"Sette","year":"2021","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.msard.2022.104195_bib0033","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/art.41914","article-title":"Humoral and cellular immune responses to SARS\u2013CoV-2 infection and vaccination in autoimmune disease patients with B cell depletion","volume":"74","author":"Simon","year":"2022","journal-title":"Arthritis Rheumatol."},{"issue":"4","key":"10.1016\/j.msard.2022.104195_bib0034","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/ana.26028","article-title":"Disease-modifying therapies and coronavirus disease 2019 severity in multiple sclerosis","volume":"89","author":"Sormani","year":"2021","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2022.104195_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104042","article-title":"Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy","volume":"80","author":"Sormani","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.msard.2022.104195_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102341","article-title":"Negative SARS-CoV-2 antibody testing following COVID-19 infection in Two MS patients treated with ocrelizumab","volume":"44","author":"Thornton","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"5","key":"10.1016\/j.msard.2022.104195_bib0037","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.11497","article-title":"Factors associated with serological response to SARS-CoV-2 vaccination in patients with multiple sclerosis treated with rituximab","volume":"5","author":"Tolf","year":"2022","journal-title":"JAMA Netw. Open"},{"issue":"43","key":"10.1016\/j.msard.2022.104195_bib0038","doi-asserted-by":"crossref","DOI":"10.21105\/joss.01686","article-title":"Welcome to the Tidyverse","volume":"4","author":"Wickham","year":"2019","journal-title":"J. Open Source Softw."},{"issue":"10","key":"10.1016\/j.msard.2022.104195_bib0039","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1177\/1352458520943791","article-title":"Recovery from COVID-19 in a B cell-depleted multiple sclerosis patient","volume":"26","author":"Wurm","year":"2020","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2022.104195_bib0040","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.bbrc.2020.10.012","article-title":"Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies","volume":"538","author":"Yuan","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"10","key":"10.1016\/j.msard.2022.104195_bib0041","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1111\/ene.14690","article-title":"COVID-19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response","volume":"28","author":"Zabalza","year":"2021","journal-title":"Eur. J. Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822007003?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822007003?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:04:35Z","timestamp":1761901475000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034822007003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":41,"alternative-id":["S2211034822007003"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2022.104195","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Longitudinal COVID-19 immune trajectories in patients with neurological autoimmunity on anti-CD20 therapy","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2022.104195","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104195"}}